Comparative nephroprotective efficacy of malonic acid derivatives (etmaben and maloben) in renal ischemia-reperfusion injury in rats

Introduction. This study assessed the nephroprotective potential of malonic acid derivatives (MADs) in acute and subacute ischemic renal injury. A model of prerenal failure was simulated using 60-minute warm renal ischemia.

Aim. To study the nephroprotective effect of MADs in acute and subacute ischemic renal failure.

Materials and methods. The experiment was conducted using a model of warm renal ischemia induced by 60-minute occlusion of the right renal artery. During a month-long monotherapy course, the effects of 4-[(3-ethoxy-3-oxopropanoyl) amino]benzoic acid (etmaben, 60 mg/kg) and sodium 4,4'-(propanediamido)dibenzoate (maloben, 60 mg/kg) were compared with the reference drug, ethylmethylhydroxypyridine succinate (Mexidol®, 50 mg/kg). To assess renal function on days 3 and 30 after ischemia, serum creatinine and urea concentrations, glomerular filtration rate (GFR), creatinine clearance, electrolyte excretion rate, and antioxidant gene expression were analyzed, and histological examination was performed.

Results and discussion. The obtained data indicate the significant efficacy of MADs in the treatment of acute ischemic kidney injury. In the group of animals receiving etmaben, a statistically significant decrease in serum creatinine and urea levels, as well as an increase in glomerular filtration rate, was observed, with no significant effect on diuresis. Maloben, in turn, had a more pronounced effect on diuresis and electrolyte excretion during the acute period. Both studied compounds demonstrated the ability to improve renal excretory function, manifested by increased creatinine elimination and a reduction in the severity of the oligoanuric phase of acute nephropathy.

Conclusion. It was found that the studied drugs activate renal excretory function, contribute to the normalization of creatinine clearance and the attenuation of the manifestations of acute oligoanuric syndrome, stabilizing the condition of animals with acute kidney injury.

1. Cai J., Chen X., Liu X., Li Z., Shi A., Tang X., Xia P., Zhang J., Yu P. AMPK: The key to ischemia-reperfusion injury. Journal of Cellular Physiology. 2022;237(11):4079– 4096. https://doi.org/10.1002/jcp.30875

2. Zhang M., Liu Q., Meng H., Duan H., Liu X., Wu J., Gao F., Wang S., Tan R., Yuan J. Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets. Signal Transduction and Targeted Therapy. 2024;9:12. https://doi.org/10.1038/s41392-023-01688-x

3. Cheung T. Y., Lam K., Leung S. C., Rainer T. H. Clinical epidemiology and outcomes of emergency department-acute kidney injury: A systematic review. Heliyon. 2024;10(9):e30580. https://doi.org/10.1016/j.heliyon.2024.e30580

4. Kellum J. A., Zarbock A. Why interventions to prevent acute kidney injury are needed now and why preventing long-term outcomes will only come later. Intensive Care Medicine. 2025;51(10):1898–1900. https://doi.org/10.1007/s00134-025-08080-z

5. Chouchani E. T., Murphy M. P. Succinate links ischaemia to reperfusion injury. Nature Metabolism. 2022;4(2):149–150.

6. Oh C. J., Kim M.-J., Lee J.-M., Kim D. H., Kim I.-Y., Park S., Kim Y., Lee K.-B., Lee S.-H., Lim C. W., Kim M., Lee J.-Y., Pagire H. S., Pagire S. H., Bae M. A., Chanda D., Thoudam T., Khang A. R., Harris R. A., Ahn J. H., Jeon J.-H., Lee I.-K. Inhibition of pyruvate dehydrogenase kinase 4 ameliorates kidney ischemia-reperfusion injury by reducing succinate accumulation during ischemia and preserving mitochondrial function during reperfusion. Kidney International. 2023;104(4):724–739. https://doi.org/10.1016/j.kint.2023.06.022

7. Karnakova P. K., Komarov T. N., Archakova O. A., Ivkin D. Yu., Vetrova E. S., Terninko I. I., Shohin I. E., Narkevich I. A. Development and validation of an HPLCMS/MS method for the quantitative determination of etmaben in human blood plasma. Drug development & registration. 2024;13(1):257–271. (In Russ.) https://doi.org/10.33380/2305-2066-2024-13-1-1752

8. Sorby-Adams A., Prime T. A., Miljkovic J. L., Prag H. A., Krieg T., Murphy M. P. A model of mitochondrial superoxide production during ischaemia-reperfusion injury for therapeutic development and mechanistic understanding. Redox Biology. 2024;72:103161. https://doi.org/10.1016/j.redox.2024.103161

9. Cao M., Zhao X., Xia F., Shi M., Zhao D., Li L., Jiang H. Mitochondrial dysfunction and metabolic reprogramming in acute kidney injury: mechanisms, therapeutic advances, and clinical challenges. Frontiers in Physiology. 2025;16:1623500. https://doi.org/10.3389/fphys.2025.1623500

10. Valls-Lacalle L., Consegal M., Ganse F. G., Yáñez-Bisbe L., Pastor J., Ruiz-Meana M., Inserte J., Benito B., Ferreira-González I., Rodríguez-Sinovas A. Long-Term Protective Effects of Succinate Dehydrogenase Inhibition during Reperfusion with Malonate on Post-Infarction Left Ventricular Scar and Remodeling in Mice. International Journal of Molecular Sciences. 2024;25(8):4366. https://doi.org/10.3390/ijms25084366

11. Prag H. A., Aksentijevic D., Dannhorn A., Giles A. V., Mulvey J. F., Sauchanka O., Du L., Bates G., Reinhold J., Kula-Alwar D., Xu Z., Pellerin L., Goodwin R. J. A., Murphy M. P., Krieg T. Ischemia-Selective Cardioprotection by Malonate for Ischemia/Reperfusion Injury. Circulation Research. 2022;131(6):528–541. https://doi.org/10.1161/CIRCRESAHA.121.320717

12. Okovityy S. V., Ivkin D. Yu., Anisimova N. A., Belykh M. A., Spasenkova O. M., Kirillova N. V., Yakovlev I. P., Chernov N. M. Antisteatotic agent. Patent RUS No RU 2702003 C1. 2019. Available at: https://patents.google.com/patent/RU2702003C1/ru Accessed: 15.04.2026. (In Russ.)

13. Ivkin D. Yu., Zelentsova A. B., Krasnova M. V., Karpov A. A., Pazheltsev V. V., Napalkova S. M., Terninko I. I., Titovich I. A., Okovitiy S. V. Comparative efficacy study of experimental chronic heart failure. Drug development & registration. 2025;14(1):349–357. (In Russ.) https://doi.org/10.33380/2305-2066-2025-14-1-1998

14. Xu B., Zhu Z., Shu H., Wang H., Lu X., Zhu X. Succinate links TCA cycle dysfunction to inflammation by activating HIF-1α signaling in acute kidney injury. International Immunopharmacology. 2025;161:115105. https://doi.org/10.1016/j.intimp.2025.115105

15. Chen Y., Li Z., Zhang H., Chen H., Hao J., Liu H., Li X. Mitochondrial metabolism and targeted treatment strategies in ischemic-induced acute kidney injury. Cell Death Discovery. 2024;10(1):69.

16. Sies H., Jones D. P. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nature Reviews Molecular Cell Biology. 2020;21(7):363–383. https://doi.org/10.1038/s41580-020-0230-3

17. Aparicio-Trejo O. E., Pedraza-Chaverri J. Mitochondria as a key target in the treatment of chronic kidney disease. Archives of Medical Research. 2023;54(7):102882.